Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Anna Silvia Wenning

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7684-6481; OpenAlex author ID A5038300273. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 10

  1. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
  2. RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2026.101010↗
  3. ASO Visual Abstract: Initiation and Completion of Adjuvant Chemotherapy After Total versus Partial Pancreaticoduodenectomy for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18579-w↗
  4. Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies patient subgroups with adverse outcome. Co-author DOI 10.1186/s12885-025-14751-3↗
  5. Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18378-3↗
  6. Impact of Routine and Selective Preoperative Endoscopic Retrograde Cholangiopancreatography with Stent Placement on Postoperative and Oncologic Outcomes Follow… First author DOI 10.3390/biomedicines13020333↗
  7. Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-24-0368↗
  8. Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal… First author DOI 10.1016/j.surg.2023.03.007↗
  9. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. First author DOI 10.1136/gutjnl-2022-329371↗
  10. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Co-author DOI 10.1016/j.ejca.2022.03.033↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beat Gloor · 10 shared papers, 2022–2026 · strength 2.41
  2. Pauline Aeschbacher · 7 shared papers, 2023–2026 · strength 1.72
  3. Andréas Andreou · 5 shared papers, 2022–2026 · strength 1.16
  4. Aurel A. Perren · 4 shared papers, 2022–2026 · strength 0.97
  5. Eva Karamitopoulou · 4 shared papers, 2022–2026 · strength 0.97
  6. Konstantin Bräutigam · 3 shared papers, 2025–2026 · strength 0.82
  7. Animesh Acharjee · 3 shared papers, 2023–2026 · strength 0.77
  8. Romy Weber · 2 shared papers, 2025–2026 · strength 0.53
  9. Martin D. Berger · 2 shared papers, 2025–2026 · strength 0.53
  10. Martin Wartenberg · 2 shared papers, 2025–2026 · strength 0.48
  11. Shadi Katou · 2 shared papers, 2023–2025 · strength 0.42
  12. Benjamin Struecker · 2 shared papers, 2023–2025 · strength 0.42
  13. Michael Guenther · 1 shared paper, 2026 · strength 0.23
  14. Nic G. Reitsam · 1 shared paper, 2026 · strength 0.23
  15. Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
  16. Bruno Märkl · 1 shared paper, 2026 · strength 0.23
  17. Przemyslaw Grochowski · 1 shared paper, 2026 · strength 0.23
  18. Robert Grützmann · 1 shared paper, 2026 · strength 0.23
  19. Christian P. Pilarsky · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.